BigHat Biosciences News

Latest BigHat Biosciences news, funding rounds and robotics & AI coverage. $75M raised. 1 article tracked by The Robotics Media.

About BigHat Biosciences

BigHat Biosciences is an AI-first biotech developing antibody therapeutics through Milner, its agentic data platform that couples large biological models with automated wet-lab experimentation. The San Mateo–based company advanced its first clinical candidate BHB810 into Phase 1 in gastric cancer in 2026 and is expanding a preclinical pipeline of avidity-driven T-cell engagers.

Key facts

• Headquarters: San Mateo, California, United States
• Country: United States
• Founded: 2019
• Sectors: AI Foundation Models, Digital Health
• Website: https://www.bighatbio.com/

Products by BigHat Biosciences

• BHB810 (Software, 2026) — CDH17-directed antibody-drug conjugate (ADC) for gastric cancer, designed by BigHat Milner platform. First patient dosed in Phase 1 in 2026.
• Milner Platform (Software, 2024) — BigHat autonomous AI and experimental platform: large biological models paired with high-throughput wet-lab automation for rapid protein and antibody design.

Funding rounds

• Series C — $75M — 2026 — led by DFJ Growth

Latest BigHat Biosciences news

• BigHat Biosciences Closes $75M Series C, Pushes AI-Designed ADC Into Phase 1 — DFJ Growth and Premji Invest co-lead BigHat's $75M Series C as its first Milner-designed antibody, BHB810, doses first patient in gastric cancer trial...